Comparison of different clones (WT49 versus 6F-H2) of WT-1 antibodies for immunohistochemical diagnosis of malignant pleural mesothelioma

Applied Immunohistochemistry and Molecular Morphology

Volumn 17, Issue 2, 2009, Pages 126-130

  Tsuta, Koji ^a   Kato, Yasufumi ^a   Tochigi, Naobumi ^b   Hoshino, Tatsuhiro ^a   Takeda, Yuji ^a   Hosako, Mutsumi ^b   Maeshima, Akiko Miyagi ^a   Asamura, Hisao ^a   Kondo, Tadashi ^b   Matsuno, Yoshihiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Immunohistochemistry; Lung carcinoma; Malignant pleural mesothelioma; WT 1

Indexed keywords

MONOCLONAL ANTIBODY 6F H2; MONOCLONAL ANTIBODY WT49; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; WT1 PROTEIN;

ARTICLE; CELL NUCLEUS; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOPLASM; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CARCINOMA; MALIGNANT MESOTHELIOMA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STAINING; SYNOVIAL SARCOMA;

ANTIBODIES, MONOCLONAL; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; PLEURAL NEOPLASMS; SENSITIVITY AND SPECIFICITY; WT1 PROTEINS;

EID: 67849135628     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e318187dd26     Document Type: Article

References (22)

1. Foster MR, Johnson JE, Olson SJ, et al. Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT-1 in malignant mesothelioma and primary pulmonary adenocarcinoma. Arch Pathol Lab Med. 2001;125:1316-1320.
2. Cury PM, Butcher DN, Fisher C, et al. Value of the mesotheliumassociated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Mod Pathol. 2000;13: 107-112. (Pubitemid 30109095)
3. Chu AY, Litzky LA, Pasha TL, et al. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol. 2005;18:105-110.
4. Pelletier J, Schalling M, Buckler AJ, et al. Expression of the Wilms' tumor gene WT1 in the murine urogenital system. Genes Dev. 1991; 5:345-356. (Pubitemid 21906043)
5. Pritchard-Jones K, Fleming S, Davidson D, et al. The candidate Wilms' tumour gene is involved in genitourinary development. Nature. 1990;346:194-197. (Pubitemid 20221639)
6. Hosono S, Gross I, English MA, et al. E-cadherin is a WT1 target gene. J Biol Chem. 2000;275:10943-10953.
7. Mayo MW, Wang CY, Drouin SS, et al. WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene. EMBO J. 1999;18:3990-4003.
8. Ordonez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol. 2003;27:1031-1051. (Pubitemid 36909525)
9. Amin KM, Litzky LA, Smythe WR, et al. Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol. 1995;146:344-356.
10. Kumar-Singh S, Segers K, Rodeck U, et al. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis. J Pathol. 1997;181:67-74. (Pubitemid 27099776)
11. Oates J, Edwards C. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology. 2000;36:341-347. (Pubitemid 30198916)
12. Ordonez NG. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol. 2000;24:598-606.
13. Miettinen M, Limon J, Niezabitowski A, et al. Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities and differences with malignant mesothelioma. Am J Surg Pathol. 2001;25:610-617. (Pubitemid 32423358)
14. Pan CC, Chen PC, Chou TY, et al. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma. Hum Pathol. 2003;34:1156-1162.
15. Kushitani K, Takeshima Y, Amatya VJ, et al. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma. Pathol Int. 2007;59:190-199. (Pubitemid 46279947)
16. Yaziji H, Battifora H, Barry TS, et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol. 2006;19:514-523.
17. Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Mod Pathol. 2006;19: 417-428. (Pubitemid 43276996)
18. Churg A, Roggli V, Galateau-Salle F, et al. Mesothelioma. In: Travis WD, Brambilla E, Muller-Hermelink HK, et al, eds. Pathology and Genetics: Tumors of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC; 2004:128-136.
19. Ordonez NG. Immunohistochemical diagnosis of epithelioid mesothelioma: an update. Arch Pathol Lab Med. 2005;129:1407-1414.
20. Nakatsuka S, Oji Y, Horiuchi T, et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol. 2006;19:804-814. (Pubitemid 43780450)
21. Ye Y, Raychaudhuri B, Gurney A, et al. Regulation of WT1 by phospholylation: inhibition of DNA binding, alteration of transcriptional activity and cellular translocation. EMBO J. 1996;15: 5606-5615. (Pubitemid 26385620)
22. Tsuboi A, Oka Y, Osaki T, et al. WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases. Microbiol Immunol. 2004;48:175-184. (Pubitemid 38405079)